A comparison of consistency of detecting c-MET gene amplification in peripheral blood and tumor tissue of nonsmall cell lung cancer patients
Authors:
- 31 August 2015
- journal article
- research article
- Published by Wolters Kluwer Health in Journal of Cancer Research and Therapeutics
- Vol. 11 (Suppl 1) , S63-S67
Abstract
Objective: To detect the consistency of the c-MET gene amplification in peripheral blood and tumor tissue of patients with non-small cell lung cancer (NSCLC) and discuss the clinical application value of c-MET gene amplification in peripheral blood. Materials and Methods: Real-time fluorescent quantitative polymerase chain reaction was used to test the tissues in 257 patients of NSCLCs and the peripheral blood samples in 318 patients of NSCLC, of which 185 cases of peripheral blood specimens could match the tissue samples, and detected the c-MET gene amplification in them by comparison of amplifications consistency in blood and tissue samples, and analyzed the correlation between c-MET gene amplification and clinical characteristics of patients. Results: The c-MET gene amplification rate was 9.75% in peripheral blood of 31 patients with NSCLC, and was 8.95% in 23 cancer tissues, the amplification consistency, was 81.25% in peripheral blood-tumor tissue matched samples. The difference was statistically significant ( P < 0.05). Conclusion: The consistency of the c-MET gene amplification in peripheral blood and tissue is high. c-MET gene amplification of peripheral blood could be used for clinical diagnosis and treatment in cases when tissue specimen is hard to get.Keywords
This publication has 35 references indexed in Scilit:
- Using Multiplexed Assays of Oncogenic Drivers in Lung Cancers to Select Targeted DrugsJAMA, 2014
- A phase 2 trial of dacomitinib (PF‐00299804), an oral, irreversible pan‐HER (human epidermal growth factor receptor) inhibitor, in patients with advanced non–small cell lung cancer after failure of prior chemotherapy and erlotinibCancer, 2014
- Treatment Rationale Study Design for the MetLung Trial: A Randomized, Double-Blind Phase III Study of Onartuzumab (MetMAb) in Combination With Erlotinib Versus Erlotinib Alone in Patients Who Have Received Standard Chemotherapy for Stage IIIB or IV Met-Positive Non–Small-Cell Lung CancerClinical Lung Cancer, 2012
- Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 studyThe Lancet Oncology, 2011
- Evaluation of epidermal growth factor receptor mutation status in serum DNA as a predictor of response to gefitinib (IRESSA)British Journal of Cancer, 2007
- From Tpr-Met to Met, tumorigenesis and tubesOncogene, 2007
- The tumour–stromal interaction between intratumoral c-Met and stromal hepatocyte growth factor associated with tumour growth and prognosis in non-small-cell lung cancer patientsBritish Journal of Cancer, 2004
- Efficacy of Gefitinib, an Inhibitor of the Epidermal Growth Factor Receptor Tyrosine Kinase, in Symptomatic Patients With Non–Small Cell Lung CancerJAMA, 2003
- Novel mutations of the MET proto-oncogene in papillary renal carcinomasOncogene, 1999
- Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomasNature Genetics, 1997